AngioScore is petitioning the FDA to refuse its competitor Abbott Laboratories the extension of its patent covering “rapid exchange” angioplasty catheters.
The patent covers technology that allows physicians to more easily-thread a catheter into a blood vessel during angioplasty.
The Abbott Park, Ill.-based Abbott has held the patent since September 1995, which is set to expire Oct. 29, according to the citizen’s petition filed by AngioScore.
The Fremont, Calif.-based medical device maker AngioScore was founded five years ago with Israeli venture capital funding. Last October, it completed a $30 million round of series E financing led by Telegraph Hill Partners.
“We believe that we are entitled to the patent extension in accordance with U.S. patent law based on the regulatory review period associated with (the company's drug-eluting stent product) Xience V,” according to Abbott spokesperson Adelle Infante.